English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/123847
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMuñoz-Alonso, María J.-
dc.contributor.authorMuñoz Terol, Alberto-
dc.date.accessioned2015-10-26T12:58:49Z-
dc.date.available2015-10-26T12:58:49Z-
dc.date.issued2013-
dc.identifierdoi: 10.3390/md11051677-
dc.identifierissn: 1660-3397-
dc.identifier.citationMarine Drugs 11(5): 1677-1692 (2013)-
dc.identifier.urihttp://hdl.handle.net/10261/123847-
dc.descriptionThis is an open access article distributed under the Creative Commons Attribution License.-- et al.-
dc.description.abstractPlitidepsin is an antitumor drug of marine origin currently in Phase III clinical trials in multiple myeloma. In cultured cells, plitidepsin induces cell cycle arrest or an acute apoptotic process in which sustained activation of c-Jun N-terminal kinase (JNK) plays a crucial role. With a view to optimizing clinical use of plitidepsin, we have therefore evaluated the possibility of using JNK activation as an in vivo biomarker of response. In this study, we show that administration of a single plitidepsin dose to mice xenografted with human cancer cells does indeed lead to increased phosphorylation of JNK in tumors at 4 to 12 h. By contrast, no changes were found in other in vitro plitidepsin targets such as the levels of phosphorylated-ERK, -p38MAPK or the protein p27KIP1. Interestingly, plitidepsin also increased JNK phosphorylation in spleens from xenografted mice showing similar kinetics to those seen in tumors, thereby suggesting that normal tissues might be useful for predicting drug activity. Furthermore, plitidepsin administration to rats at plasma concentrations comparable to those achievable in patients also increased JNK phosphorylation in peripheral mononuclear blood cells. These findings suggest that changes in JNK activity provide a reliable biomarker for plitidepsin activity and this could be useful for designing clinical trials and maximizing the efficacy of plitidepsin.-
dc.description.sponsorshipThis work has been partially supported by grants (Programa Cenit, CEN-20091016, SAF2010-18302 and Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III, RD12/0036/0021) from Ministerio de Economía y Competitividad of Spain.-
dc.publisherMultidisciplinary Digital Publishing Institute-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.titlec-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity-
dc.typeartículo-
dc.identifier.doi10.3390/md11051677-
dc.relation.publisherversionhttp://dx.doi.org/10.3390/md11051677-
dc.date.updated2015-10-26T12:58:49Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.rights.licensehttp://creativecommons.org/licenses/by/3.0/-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderEuropean Commission-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
plitidepsin activity.pdf1,6 MBUnknownView/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.